Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $33M in Market Capitalization this August of 2025, considering the latest stock price and the number of outstanding shares.Data for Acasti Pharma | ACST - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $52.14M in Equity Capital and Reserves for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Equity Capital And Reserves including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $0 in Loan Capital for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Loan Capital including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported 32 in Employees for its fiscal year ending in March of 2021. Data for Acasti Pharma | ACST - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $61.22M in Assets for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Assets including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported 10.14M in Outstanding Shares in January of 2025. Data for Acasti Pharma | ACST - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Grace Therapeutics income from continuous operations from 2014 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-3704000 in Operating Profit for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Operating Profit including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $11.06M in Cash and Equivalent for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Cash And Equivalent including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $1000 in Ordinary Share Capital for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Ordinary Share Capital including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Grace Therapeutics total assets from 2014 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-4829000 in EBITDA for its fiscal quarter ending in September of 2024. Data for Acasti Pharma | ACST - Ebitda including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Grace Therapeutics roa - return on assets from 2014 to 2025. Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Grace Therapeutics comprehensive income from 2014 to 2025. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-0.36 in Trade Creditors for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $1.97M in Current Liabilities for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $0 in Interest Expense on Debt for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-0.36 in Selling and Administration Expenses for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Selling And Administration Expenses including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-4155000 in Net Income for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Net Income including historical, tables and charts were last updated by Trading Economics this last August in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.